[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bclc-stage-b-hepatocellular-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bclc-stage-b-hepatocellular-carcinoma":95},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,71],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100627515",false,"NCT07449637","Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma.","Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma: An Observational Cohort Study.","Inclusion Criteria:\n\n* Aged ≥18 years.\n* Both sexes.\n* Diagnosis of hepatocellular carcinoma based on accepted radiologic or histologic criteria.\n* Classified as intermediate stage (BCLC-B) at time of decision for first-line treatment.\n* Child-Pugh A or B.\n* ECOG performance status 0-1.\n\nExclusion Criteria:\n\n* BCLC A, C, or D at diagnosis.\n* Prior curative therapy (resection, transplantation, curative ablation).\n* Missing essential data (imaging, liver function, treatment records).\n* Mixed HCC-cholangiocarcinoma.","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the different treatment options for intermediate-stage hepatocellular carcinoma. The main question it aims to answer is:\n\n\\- What are the survival outcomes among participants aged 18 or older who receive treatment for intermediate-stage hepatocellular carcinoma?",[23],"BCLC Stage B Hepatocellular Carcinoma",[25],"Intermediate-Stage Hepatocellular Carcinoma","NOT_YET_RECRUITING","2026-02-27",{"date":29,"type":30},"2026-03-04","ACTUAL",{"date":32,"type":19},"2026-03",{"date":34,"type":19},"2026-07",{"name":36,"class":37},"Sohag University","OTHER",1,{"id":40,"slug":4,"hasResults":10,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":38},"100501526","NCT05810402","Liver Cancer and Immunotherapy in the Liquid Biopsy Era","Liver Cancer and Immunotherapy : Clinical Relevance of LIquid BioPSY","LILIPSY","Inclusion Criteria:\n\n* Patients of at least 18 years old,\n* Patients with advanced hepatocellular carcinoma or HCC with indication for first-line PD-1 or PD-L1 immunotherapy in MDT, without prior systemic therapy,\n* The diagnosis of HCC is established according to imaging criteria (LI-RADSv2018 criteria) or after histological evidence,\n* Advanced HCC defined by BCLC stages B and C,\n* Patients with oral consent.\n\nExclusion Criteria:\n\n* Administration of a previous systemic anti-tumor treatment (immunotherapy or chemotherapy or targeted therapy)\n* No personal history of neoplasia in the previous 5 years\n* No personal history of systemic inflammatory diseases\n* No immunosuppressive treatment or treatment that could modify immunity (anti-TNF...)\n* No affiliation or non-beneficiary of a Social Security system;\n* Vulnerable persons according to article L1121-6 of the CSP ;\n* Persons of full age who are protected or unable to give their consent according to article L1121-8 of the CSP;\n* Pregnant or breastfeeding women according to article L1121-5 of the CSP.\n* Non-inclusion due to follow-up difficulties (transfer, insufficient motivation, poor compliance, priority associated pathology in care, etc.)",true,{"count":48,"type":19},60,"INTERVENTIONAL",[51],"NA","The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy.\n\nThe main questions it aims to answer are:\n\n* Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency?\n* Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients?\n\nParticipants blood will be collected at several time points.",[54,23,55,56,57],"Hepatocellular Carcinoma","BCLC Stage C Hepatocellular Carcinoma","Immune Checkpoint Inhibitor","Liquid Biopsy",[54,59,56,57,60],"BCLC Stage B and C","Precision Medicine","RECRUITING","2025-07-07",{"date":64,"type":30},"2025-07-10",{"date":66,"type":30},"2023-06-28",{"date":68,"type":19},"2027-05",{"name":70,"class":37},"University Hospital, Montpellier",{"id":72,"slug":4,"hasResults":10,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":38},"100564662","NCT06632093","HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC","Hepatic Arterial Infusion Chemotherapy in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced Hepatocellular Carcinoma After the Failure of Systemic Therapy Recommended by BCLC","Inclusion Criteria:\n\n1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of portal vein tumor thrombus;\n3. Has received previous systemic therapy recommended for HCC by BCLC, and the systemic therapy failed;\n4. Both PD-1inhibitors and Lenvatinib patients received only include marketed drugs but are not limited to HCC approval;\n5. HAIC was performed after the first PD-1 inhibitor\u002F Lenvatinib treatment or before treatment;\n6. Received at least 2 cycles of HAIC；\n7. Has repeated measurable intrahepatic lesions;\n8. Child-Pugh class A or B.\n\nExclusion Criteria:\n\n1. The interval between the failure of systemic therapy and the beginning of combination therapy longer than 3 months;\n2. With other malignant tumors;\n3. Unable to meet criteria of combination timeframe described above.","75 Years",{"count":79,"type":19},84,"The purpose of this study is to evaluate the safety and efficacy of hepatic arterial infusion chemotherapy (HAIC) in combination with PD-1 inhibitors and Lenvatinib in patients with intermediate or advanced-stage hepatocellular carcinoma (HCC) after failure of systemic therapy recommended by BCLC.",[23,55,82,83,84,85],"Hepatic Arterial Infusion Chemotherapy","Lenvatinib","PD-1","Systemic Therapy","2024-10-06",{"date":88,"type":30},"2024-10-08",{"date":90,"type":30},"2024-09-16",{"date":92,"type":19},"2025-12-30",{"name":94,"class":37},"First Hospital of China Medical University",""]